The Division of Hematology and Hemostaseology at the Medical University of Vienna is located in the General Hospital of Vienna and is a leading center in Europe.
Our primary goal is to provide optimal management to all patients by applying top-level services and high-quality patient care and by employing current standards in the diagnosis and therapy as well as new emerging concepts in precision medicine and translational science. Our center is embedded in a strong scientific environment at our university and in the international scientific community. Based on these collaborations, our study groups and experts are able to offer access to cutting-edge diagnostic and therapeutic approaches as well as numerous clinical trials.
Our division is a leading teaching and training center for M.D. and Ph.D. students, postdocs, and other academic personnel and is also part of the Comprehensive Cancer Center (CCC) of the Medical University of Vienna and Vienna General Hospital (AKH). Our teams are embedded in numerous national and international academic networks and clinical study groups, several of which are chaired by members of our center. Members of our center also coordinate and chair a number of national and international research clusters and institutes, including the Ludwig Boltzmann Institute of Hematology and Oncology (chair: Prof. P. Valent).
Our research teams and expert physicians focus on various disease models, including hereditary and acquired forms of cytopenia, acute and chronic leukemias, Hodgkin- and Non-Hodgkin lymphomas, myelodysplastic and myeloproliferative neoplasms, amyloidosis, multiple myeloma, aplastic anemia and PNH, mastocytosis, eosinophil disorders, histiocytosis, blood clotting disorders including hemophilia, and venous thrombosis and pulmonary embolism. Furthermore, our division runs special scientific programs in the fields of immunotherapy, gene therapy, leukemic stem cells, cell therapies, psycho-oncology, precision medicine, and telemedicine.
The overarching aim in our experimental and translational research efforts is to improve management, therapy and survival as well as the quality of life in patients with malignant and non-malignant blood cell disorders as well as patients with coagulation disorders and thromboembolic diseases.
Univ.-Prof. Dr. med. univ. Peter Valent
Interim. Head of the Division of Hematology and
Hemostaseology